Home>>Signaling Pathways>> Neuroscience>> Seizure Disorders>>Thioperamide (maleate)

Thioperamide (maleate)

Catalog No.GC45045

Thioperamide (maleate) is a selective histamine H3 receptor antagonist that crosses the blood-brain barrier.

Products are for research use only. Not for human use. We do not sell to patients.

Thioperamide (maleate) Chemical Structure

Cas No.: 148440-81-7

Size Price Stock Qty
1mg
$18.00
In stock
5mg
$77.00
In stock
10mg
$137.00
In stock
25mg
$301.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Thioperamide (maleate) is a selective histamine H3 receptor antagonist that crosses the blood-brain barrier. This compound binds to rat cerebral cortical cells in vitro with a pKi value of 8.4 and inhibits histamine binding in vivo with an ED50 value of 1 mg/kg.[1] At a dose of 5 mg/kg thioperamide (maleate) inhibits kindled seizures in rats by decreasing histamine and gamma-aminobutyric acid.[2]

Reference:
[1]. Meir, G., Apelt, J., Reichert, U., et al. Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. European Journal of Pharmaceutical Sciences 13, 249-259 (2001).
[2]. Harada, C., Fujii, Y., Hirai, T., et al. Inhibitory effect of iodophenprofit, a selective histamine H3 antagonist, on amygdaloid kindled seizures. Brain Research Bulletin 63, 143-146 (2004).

Reviews

Review for Thioperamide (maleate)

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thioperamide (maleate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.